A comparative analysis of survival and funding discrepancies in cancers with high mortality

Bradley R. Hall, Andrew Cannon, Pranita Atri, Christopher S. Wichman, Lynette M. Smith, Sushil Kumar, Surinder K. Batra, Hongmei Wang, Apar Kishor Ganti, Aaron R. Sasson, Chandrakanth Are

Research output: Contribution to journalArticle

Abstract

Objective:Comparative analyses of survival and funding statistics in cancers with high mortality were performed to quantify discrepancies and identify areas for intervention.Background:Discrepancies in research funding may contribute to stagnant survival rates in pancreatic ductal adenocarcinoma (PDAC).Methods:The Surveillance, Epidemiology, and End Results database was queried for survival statistics. Funding data were obtained from the National Cancer Institute (NCI). Clinical trial data were obtained from www.clinicaltrials.gov. Cancers with high mortality were included for analyses.Results:Since 1997, PDAC has received lesser funding ($1.41 billion) than other cancers such as breast ($10.52 billion), prostate ($4.93 billion), lung ($4.80 billion), and colorectal ($4.50 billion). Similarly, fewer clinical trials have been completed in PDAC (n = 608) compared with breast (n = 1904), lung (n = 1629), colorectal (n = 1080), and prostate (n = 1055) cancer. Despite this, since 1997, dollars invested in PDAC research produced a greater return on investment with regards to 5-year overall survival (5Y-OS) compared with breast, prostate, uterine, and ovarian cancer. Incremental cost-effectiveness analysis demonstrates that millions (liver, non-Hodgkin lymphoma, and melanoma) and billions (colorectal and lung) of dollars were required for each additional 1% increase in 5Y-OS compared with PDAC. Funding of research towards early diagnosis of PDAC has decreased by 19% since 2007. For nearly all cancers, treatment-related research receives the highest percentage of NCI funding.Conclusions:Funding of PDAC research is significantly less than other cancers, despite its higher mortality and greater potential to improve 5Y-OS. Increased awareness and lobbying are required to increase funding, promote research, and improve survival.

Original languageEnglish (US)
Pages (from-to)296-302
Number of pages7
JournalAnnals of surgery
Volume271
Issue number2
DOIs
StatePublished - Feb 1 2020

Fingerprint

Survival Analysis
Adenocarcinoma
Mortality
Research
Neoplasms
National Cancer Institute (U.S.)
Lung
Prostate
Breast
Lobbying
Clinical Trials
Uterine Neoplasms
Second Primary Neoplasms
Ovarian Neoplasms
Non-Hodgkin's Lymphoma
Cost-Benefit Analysis
Early Diagnosis
Melanoma
Prostatic Neoplasms
Epidemiology

Keywords

  • discrepancy
  • funding
  • pancreatic ductal adenocarcinoma
  • survival

ASJC Scopus subject areas

  • Surgery

Cite this

A comparative analysis of survival and funding discrepancies in cancers with high mortality. / Hall, Bradley R.; Cannon, Andrew; Atri, Pranita; Wichman, Christopher S.; Smith, Lynette M.; Kumar, Sushil; Batra, Surinder K.; Wang, Hongmei; Ganti, Apar Kishor; Sasson, Aaron R.; Are, Chandrakanth.

In: Annals of surgery, Vol. 271, No. 2, 01.02.2020, p. 296-302.

Research output: Contribution to journalArticle

Hall, BR, Cannon, A, Atri, P, Wichman, CS, Smith, LM, Kumar, S, Batra, SK, Wang, H, Ganti, AK, Sasson, AR & Are, C 2020, 'A comparative analysis of survival and funding discrepancies in cancers with high mortality', Annals of surgery, vol. 271, no. 2, pp. 296-302. https://doi.org/10.1097/SLA.0000000000003042
Hall, Bradley R. ; Cannon, Andrew ; Atri, Pranita ; Wichman, Christopher S. ; Smith, Lynette M. ; Kumar, Sushil ; Batra, Surinder K. ; Wang, Hongmei ; Ganti, Apar Kishor ; Sasson, Aaron R. ; Are, Chandrakanth. / A comparative analysis of survival and funding discrepancies in cancers with high mortality. In: Annals of surgery. 2020 ; Vol. 271, No. 2. pp. 296-302.
@article{008a42e99b6b48cfb189f6ea3b52459d,
title = "A comparative analysis of survival and funding discrepancies in cancers with high mortality",
abstract = "Objective:Comparative analyses of survival and funding statistics in cancers with high mortality were performed to quantify discrepancies and identify areas for intervention.Background:Discrepancies in research funding may contribute to stagnant survival rates in pancreatic ductal adenocarcinoma (PDAC).Methods:The Surveillance, Epidemiology, and End Results database was queried for survival statistics. Funding data were obtained from the National Cancer Institute (NCI). Clinical trial data were obtained from www.clinicaltrials.gov. Cancers with high mortality were included for analyses.Results:Since 1997, PDAC has received lesser funding ($1.41 billion) than other cancers such as breast ($10.52 billion), prostate ($4.93 billion), lung ($4.80 billion), and colorectal ($4.50 billion). Similarly, fewer clinical trials have been completed in PDAC (n = 608) compared with breast (n = 1904), lung (n = 1629), colorectal (n = 1080), and prostate (n = 1055) cancer. Despite this, since 1997, dollars invested in PDAC research produced a greater return on investment with regards to 5-year overall survival (5Y-OS) compared with breast, prostate, uterine, and ovarian cancer. Incremental cost-effectiveness analysis demonstrates that millions (liver, non-Hodgkin lymphoma, and melanoma) and billions (colorectal and lung) of dollars were required for each additional 1{\%} increase in 5Y-OS compared with PDAC. Funding of research towards early diagnosis of PDAC has decreased by 19{\%} since 2007. For nearly all cancers, treatment-related research receives the highest percentage of NCI funding.Conclusions:Funding of PDAC research is significantly less than other cancers, despite its higher mortality and greater potential to improve 5Y-OS. Increased awareness and lobbying are required to increase funding, promote research, and improve survival.",
keywords = "discrepancy, funding, pancreatic ductal adenocarcinoma, survival",
author = "Hall, {Bradley R.} and Andrew Cannon and Pranita Atri and Wichman, {Christopher S.} and Smith, {Lynette M.} and Sushil Kumar and Batra, {Surinder K.} and Hongmei Wang and Ganti, {Apar Kishor} and Sasson, {Aaron R.} and Chandrakanth Are",
year = "2020",
month = "2",
day = "1",
doi = "10.1097/SLA.0000000000003042",
language = "English (US)",
volume = "271",
pages = "296--302",
journal = "Annals of Surgery",
issn = "0003-4932",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - A comparative analysis of survival and funding discrepancies in cancers with high mortality

AU - Hall, Bradley R.

AU - Cannon, Andrew

AU - Atri, Pranita

AU - Wichman, Christopher S.

AU - Smith, Lynette M.

AU - Kumar, Sushil

AU - Batra, Surinder K.

AU - Wang, Hongmei

AU - Ganti, Apar Kishor

AU - Sasson, Aaron R.

AU - Are, Chandrakanth

PY - 2020/2/1

Y1 - 2020/2/1

N2 - Objective:Comparative analyses of survival and funding statistics in cancers with high mortality were performed to quantify discrepancies and identify areas for intervention.Background:Discrepancies in research funding may contribute to stagnant survival rates in pancreatic ductal adenocarcinoma (PDAC).Methods:The Surveillance, Epidemiology, and End Results database was queried for survival statistics. Funding data were obtained from the National Cancer Institute (NCI). Clinical trial data were obtained from www.clinicaltrials.gov. Cancers with high mortality were included for analyses.Results:Since 1997, PDAC has received lesser funding ($1.41 billion) than other cancers such as breast ($10.52 billion), prostate ($4.93 billion), lung ($4.80 billion), and colorectal ($4.50 billion). Similarly, fewer clinical trials have been completed in PDAC (n = 608) compared with breast (n = 1904), lung (n = 1629), colorectal (n = 1080), and prostate (n = 1055) cancer. Despite this, since 1997, dollars invested in PDAC research produced a greater return on investment with regards to 5-year overall survival (5Y-OS) compared with breast, prostate, uterine, and ovarian cancer. Incremental cost-effectiveness analysis demonstrates that millions (liver, non-Hodgkin lymphoma, and melanoma) and billions (colorectal and lung) of dollars were required for each additional 1% increase in 5Y-OS compared with PDAC. Funding of research towards early diagnosis of PDAC has decreased by 19% since 2007. For nearly all cancers, treatment-related research receives the highest percentage of NCI funding.Conclusions:Funding of PDAC research is significantly less than other cancers, despite its higher mortality and greater potential to improve 5Y-OS. Increased awareness and lobbying are required to increase funding, promote research, and improve survival.

AB - Objective:Comparative analyses of survival and funding statistics in cancers with high mortality were performed to quantify discrepancies and identify areas for intervention.Background:Discrepancies in research funding may contribute to stagnant survival rates in pancreatic ductal adenocarcinoma (PDAC).Methods:The Surveillance, Epidemiology, and End Results database was queried for survival statistics. Funding data were obtained from the National Cancer Institute (NCI). Clinical trial data were obtained from www.clinicaltrials.gov. Cancers with high mortality were included for analyses.Results:Since 1997, PDAC has received lesser funding ($1.41 billion) than other cancers such as breast ($10.52 billion), prostate ($4.93 billion), lung ($4.80 billion), and colorectal ($4.50 billion). Similarly, fewer clinical trials have been completed in PDAC (n = 608) compared with breast (n = 1904), lung (n = 1629), colorectal (n = 1080), and prostate (n = 1055) cancer. Despite this, since 1997, dollars invested in PDAC research produced a greater return on investment with regards to 5-year overall survival (5Y-OS) compared with breast, prostate, uterine, and ovarian cancer. Incremental cost-effectiveness analysis demonstrates that millions (liver, non-Hodgkin lymphoma, and melanoma) and billions (colorectal and lung) of dollars were required for each additional 1% increase in 5Y-OS compared with PDAC. Funding of research towards early diagnosis of PDAC has decreased by 19% since 2007. For nearly all cancers, treatment-related research receives the highest percentage of NCI funding.Conclusions:Funding of PDAC research is significantly less than other cancers, despite its higher mortality and greater potential to improve 5Y-OS. Increased awareness and lobbying are required to increase funding, promote research, and improve survival.

KW - discrepancy

KW - funding

KW - pancreatic ductal adenocarcinoma

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=85070740805&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070740805&partnerID=8YFLogxK

U2 - 10.1097/SLA.0000000000003042

DO - 10.1097/SLA.0000000000003042

M3 - Article

C2 - 30188400

AN - SCOPUS:85070740805

VL - 271

SP - 296

EP - 302

JO - Annals of Surgery

JF - Annals of Surgery

SN - 0003-4932

IS - 2

ER -